 - Dose Expansion: Histologically confirmed and documented, previously untreated or treated stage IIIB or IV Non-Small Cell Lung Cancer NSCLC having failed no more than 1 previous platinum containing chemotherapy regimen for locally advanced or metastatic disease or relapsedrefractory locally advanced or metastatic gastric adenocarcinoma having failed no more than 2 previous chemotherapy regimen for locally advanced or metastatic disease. Subjects with NSCLC who are known to be epidermal growth factor receptor EGFR-mutation positive must have received an EGFR inhibitor and subjects known to be anaplastic lymphoma kinase ALK-mutation positive must have received an ALK inhibitor. 